The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | 4,107,334 | - |
| Stock-based compensation | 0 | 3,485 |
| Amortization | 92,378 | - |
| Net loss | - | -2,871,400 |
| Inventory | 0 | -1,200 |
| Prepaids and other current assets | -52,557 | -105,114 |
| Accounts payable | -16,291 | -10,080 |
| Amortization | - | 61,319 |
| Accrued expenses | 0 | -39,920 |
| Net cash used in operating activities | -1,168,609 | -2,750,282 |
| Redemptions of investments | 0 | 0 |
| Payment of patent purchase obligation - related party | 0 | - |
| Net cash provided by investing activities | 0 | 0 |
| Purchase of treasury stock | 0 | 10,000 |
| Proceeds from exercise of warrants, net of issuance costs | 0 | 3,364,000 |
| Proceeds from sale of series b preferred stock | 0 | 0 |
| Net cash provided by (used in) financing activities | 0 | 3,354,000 |
| Net change in cash | -1,168,609 | 603,718 |
| Cash and cash equivalents at beginning of period | 5,940,402 | - |
| Cash and cash equivalents at end of period | 5,375,511 | - |
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)